Introduction
Since the first in vitro fertilization (IVF) pregnancy and birth in 1978, many changes have occurred. Superovulation with clomiphene citrate and subsequent different gonadotropin preparations is widely used instead of natural cycles, in order to produce a large number of oocytes. However, the premature luteinizing hormone (LH) surge that may occur during ovarian hyperstimulation reduces the effectiveness of the regimen and negatively affects oocyte and embryo quality.
The introduction of a gonadotropin-releasing hormone agonist (GnRH-a) marked a new era in ovarian hyperstimulation, and different regimens have been developed to achieve an initial increase in gonadotropin secretion (flare-up) or pituitary desensitization. The GnRH-a long protocol has become the standard method at most centers.
GnRH-a offers several advantages, but ovarian stimulation with the GnRH-a long protocol has been associated with the need for a higher gonadotropin dose or even hyporesponsiveness. Recently, it was proposed that using lower doses of GnRH-a would provide the same benefit as the standard dose [1] .
In this study, we retrospectively summarized and analyzed our clinical experience of the low-dose GnRHa down-regulation protocol in our IVF program and compared the ovulatory responses and cycle outcomes with the standard-dose GnRH-a down-regulation protocol and gonadotropin-alone protocol to evaluate the advantages and disadvantages of lowering the GnRH-a dosage.
Materials and Methods

Patient population
All IVF cycles at the Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, from January 1, 1996, to December 31, 1998, were reviewed. Patients who received the GnRH-a long protocol (begun in the mid-luteal phase) and patients who received the gonadotropin-alone protocol were identified and included in the analysis.
Protocols and study design
The standard-dose GnRH-a protocol consisted of daily 1 mg leuprolide acetate subcutaneously from the midluteal phase, followed by 0.5 mg daily from the day of gonadotropin commencement. In the low-dose GnRHa protocol, the dosage of leuprolide acetate was 0.5 mg daily in the luteal phase and further reduced to 0.25 mg daily on the day of gonadotropin commencement. The gonadotropin-alone protocol consisted of gonadotropin only from day 3 of the stimulation cycle.
In all three protocols, 10,000 IU human chorionic gonadotropin (hCG) was given intramuscularly when at least two follicles reached a mean diameter of 18 mm or greater. Oocyte retrieval was performed 34 to 35 hours later. The luteal phase was supplemented with 25-50 mg progesterone-in-oil daily until the appearance of embryonic heart motion or proven failure to conceive. hCG at 5,000 IU was also given on the fifth day after oocyte retrieval for luteal reinforcement, except in patients at risk for hyperstimulation syndrome.
Patient characteristics, ovulatory responses, and pregnancy outcomes were analyzed using the t test and Chi-squared test, with p less than 0.05 defining a significant difference.
Results
A total of 181 IVF cycles met our criteria, including 48 cycles with the low-dose GnRH-a protocol (group 1), 37 cycles with the standard-dose GnRH-a protocol (group 2), and 96 cycles with the gonadotropin-alone protocol (group 3). There were no significant differences in terms of age, cause of infertility, or duration of infertility among the three groups (Tables 1 and 2 ). However, more patients in group 1 suffered from primary infertility.
The responses to ovarian stimulation for each protocol are presented in Table 3 . Patients in both groups 1 and 2 required higher gonadotropin doses and more days of stimulation than patients in group 3. Preovulatory peak serum estradiol (E2) concentration and number of retrieved oocytes in group 1 were similar to groups 2 and 3, but group 1 patients required more stimulation days and higher total gonadotropin doses. The pregnancy rates were higher in both long-protocol groups than the gonadotropin-alone group (36.4% and 29.7% vs 22.9%), but the differences were not significant (Table 4 ). There were also no significant differences in terms of abortion rates and multiple pregnancy rates. Furthermore, no spontaneous LH surge occurred in group 1 or 2 patients.
Discussion
The addition of GnRH-a to ovulation induction protocols has been claimed to play a significant role in improving assisted reproduction technology (ART) cycle outcomes, including lower cancellation rates (by suppressing endogenous LH surges) [2] , higher oocyte yields [3, 4] , higher pregnancy rates [2] , and lower miscarriage rates in some individuals [5] . We found higher pregnancy rates and live birth rates in the GnRH-a long protocol groups than in the gonadotropin-alone group, though the differences were not significant. However, the minimal effective dosage is still under investigation. Sandow et al showed that the doses required to maintain pituitary suppression decrease with the length of treatment [6] , and Janssens et al showed that as little as 15-50 µg triptorelin acetate daily is enough for pituitary desensitization [7] . Halving the dosage of leuprolide acetate depot also provides adequate pituitary desensitization [1] . In this study, no spontaneous LH surge occurred in the low-dose group, which further convinced us that low-dose GnRH-a can be applied clinically with confidence.
The rationale for lowering the GnRH-a dosage is to decrease pituitary suppression and, hence, to obtain a better ovarian response. Some authors have shown benefits, with increased numbers of oocytes recovered or lower total gonadotropin dosages in poor responders [8] [9] [10] [11] . However, in this study, we found that the low-dose GnRH-a group needed more days of stimulation and a higher total gonadotropin dose, which is in conflict with our original assumption.
As previously reported, delayed initiation of gonadotropin stimulation in the GnRH-a long protocol (administering a higher total GnRH-a dose before initiation of gonadotropin) was associated with a significant decrease in the subsequent duration of gonadotropin stimulation [12] . If we account for the inverse relationship between GnRH-a dosage and total gonadotropin dose in that report and our data, the GnRH-a administered for ovarian hyperstimulation may exert effects not simply through pituitary axis suppression. Some reports have addressed how GnRH-a can modulate ovarian steroidogenesis by direct action [13] ; the different effects might depend on the degree of follicular maturation and/or the type of gonadotropin used [14] . Furthermore, GnRH-a can exert different stimulating and inhibiting effects on ovarian steroidogenesis in cultured human granulosa cells due to the absence or presence of gonadotropins in the culture medium [13] . The modulation effects of GnRH-a on ovarian hyperstimulation may be more complex than previously thought. The low dose of 
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GnRH-a we used was high enough for complete pituitary desensitization but might possibly diminish the beneficial direct ovarian effect. Most trials reducing the GnRH-a dosage were nonrandomized and applied to poor responders [8] [9] [10] . Kowalik and colleagues reviewed their database of patients who underwent at least two cycles of IVF with different leuprolide dosages, and noted that lowering the GnRH-a dosage resulted in a faster rise in E2 concentration and a higher peak E2 concentration, but no difference in oocyte yields [11] . However, in our IVF program, the low-dose group was associated with similar oocyte yields and higher (though not significantly) peak E2 concentrations, but a higher gonadotropin dose was needed. This may have been due to the bias in judging the timing of ovulation induction. However, if the effects of GnRH-a on the ovary are so complex, maybe the different ovarian hyperstimulation protocols and different races (or different mean body weights, hence, different serum concentrations for the same GnRH-a dosage) contribute to the divergent results.
Our clinical experience has shown that the use of low-dose GnRH-a can effectively prevent a spontaneous LH surge and achieve similar pregnancy rates as the standard dose. Furthermore, the decreased costs of the lower GnRH-a dosage may overcome the cost of increased gonadotropin use. In fact, the total costs of gonadotropin plus GnRH-a were NT$25,600 ± 4,913 and NT$28,312 ± 5,027 in groups 1 and 2, respectively, and these were economically favorable.
In summary, the low-dose GnRH-a down-regulation protocol can be considered an alternative to the standard-dose protocol. However, more studies are needed to further evaluate the mechanisms of GnRH-a dosage in ovarian hyperstimulation before we can find the optimal GnRH-a dosage for ovarian hyperstimulation in clinical IVF.
